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Glutamate is the principal excitatory neurotransmitter in brain. Although it is rapidly
synthesized from glucose in neural tissues the biochemical processes for replenishing
the neurotransmitter glutamate after glutamate release involve the glutamate–glutamine
cycle. Numerous in vivo 13C magnetic resonance spectroscopy (MRS) experiments since
1994 by different laboratories have consistently concluded: (1) the glutamate–glutamine
cycle is a major metabolic pathway with a flux rate substantially greater than those
suggested by early studies of cell cultures and brain slices; (2) the glutamate–glutamine
cycle is coupled to a large portion of the total energy demand of brain function.
The dual roles of glutamate as the principal neurotransmitter in the CNS and as a
key metabolite linking carbon and nitrogen metabolism make it possible to probe
glutamate neurotransmitter cycling using MRS by measuring the labeling kinetics
of glutamate and glutamine. At the same time, comparing to non-amino acid
neurotransmitters, the added complexity makes it more challenging to quantitatively
separate neurotransmission events from metabolism. Over the past few years our
understanding of the neuronal-astroglial two-compartment metabolic model of the
glutamate–glutamine cycle has been greatly advanced. In particular, the importance
of isotopic dilution of glutamine in determining the glutamate–glutamine cycling rate
using [1−13C] or [1,6-13C2] glucose has been demonstrated and reproduced by different
laboratories. In this article, recent developments in the two-compartment modeling of the
glutamate–glutamine cycle are reviewed. In particular, the effects of isotopic dilution of
glutamine on various labeling strategies for determining the glutamate–glutamine cycling
rate are analyzed. Experimental strategies for measuring the glutamate–glutamine cycling
flux that are insensitive to isotopic dilution of glutamine are also suggested.
Keywords: glutamate, glutamine, magnetic resonance spectroscopy, glucose metabolism, CNS, metabolic
modeling, acetate
INTRODUCTION
Glutamate is the principal excitatory neurotransmitter in brain.
At low concentrations it excites virtually all neurons in the CNS.
Excessive activation of glutamate receptors by glutamate can
result in a number of pathological conditions and can lead to cell
death. As a zwitterionic molecule glutamate cannot diffuse across
cell membranes. It is well understood that glutamate uptake plays
important roles in regulating the extracellular concentration of
glutamate in the brain. Both in vivo and in vitro studies have
indicated that glutamate released by neurons is rapidly taken
up by astroglial cells, via high-affinity Na+-dependent glutamate
transporters. Evidence from studies using antisense mRNA to
selectively knock down neuronal and astroglial transporters, as
well as direct measurements of glutamate-gated ionic currents,
support the hypothesis that almost all released glutamate is taken
up by astroglia in the cerebral cortex (Rothstein, 1996; Bergles
et al., 1999). Subsequently, glutamate is either converted into glu-
tamine by glutamine synthetase, which is exclusively localized
in glial cells (Martinez-Hernandez et al., 1977), or oxidized by
assimilation into the Krebs cycle located in the mitochondria of
astroglial cells. Although glutamate is rapidly synthesized from
glucose in neural tissues the biochemical processes for replenish-
ing the neurotransmitter glutamate after glutamate release involve
the glutamate–glutamine cycle (Cerdán et al., 1990; Erecin´ska and
Silver, 1990). Glutamine, formed by amidization of glutamate,
is readily discharged from astroglial cells by facilitated diffusion
via Na+ and H+-coupled, electroneutral systems-N transporters.
Glutamine readily enters nerve terminals mainly by electro-
genic systems-A transporters (Chaudhry et al., 2002). There
glutaminase converts it back into glutamate which can be again
used for neuronal transmission or assimilated into the neuronal
Krebs cycle.
The existence of this glutamate–glutamine cycle was ini-
tially proposed based on the multiple findings: (1) isolated
nerve terminals contain the majority of tissue content of glu-
taminase but no glutamine synthetase, the latter is found to
be exclusively located in glial cells (Martinez-Hernandez et al.,
1977; Hertz, 1979); (2) biochemical and autoradiographic stud-
ies clearly demonstrated that glutamate is selectively accumu-
lated by glial cells and rapidly converted into glutamine; (3)
by comparison, glutamine preferentially enters neurons where
it is converted in large proportions into glutamate (Duce et al.,
1983). The glutamate–glutamine cycling pathway between neu-
rons and astroglia has been studied extensively in vivo, in cell
culture, and in brain slices using isotope tracers (e.g., Shank et al.,
1993; Lapidot and Gopher, 1994). Despite the large amount of
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evidence for its existence, early kinetic studies considered that
the glutamate–glutamine cycling flux is small and makes only a
minor contribution to brain energy metabolism. Consistent with
this early notion, the fraction of glutamate participating in the
glutamate–glutamine cycle was considered small, leading to the
conceptualization of a neurotransmitter glutamate pool and a
separate metabolic glutamate pool (Erecin´ska and Silver, 1990).
This compartmentalization of neuronal glutamate is supported
by the experimental findings of a low rate of label incorpo-
ration in cell cultures and in non-electrically stimulated brain
slices from various labeled precursors (e.g., Badar-Goffer et al.,
1992).
The initial detection of glucose metabolism using in vivo 13C
magnetic resonance spectroscopy (MRS) found rapid and sig-
nificant labeling of glutamine (Gruetter et al., 1994), which is
predominantly located in the astroglial cells. This in vivo evidence
suggests rapid transfer of 13C labels from the predominantly neu-
ronal glutamate compartment to the predominantly astroglial
glutamine compartment. Subsequent studies on human and ani-
mal brains using refined MRS techniques and various 13C-labeled
substrates have consistently contradicted the concept of a small,
metabolically inactive neurotransmitter glutamate pool (for a
recent review, see, for example, Rothman et al., 2011). Using
[1-13C] glucose or [1,6-13C2] glucose infusion, which predomi-
nantly labels neuronal glutamate due to the high energy demand
by neurons, rapid and significant labeling of glutamine C2–C4
has been consistently reproduced by all studies employing either
direct 13C detection or the more sensitive indirect proton detec-
tion. Using [2-13C] glucose or [2,5-13C2] glucose and direct 13C
detection of carboxyl/amide carbons the similar labeling of glu-
tamine C5 was also found (Li et al., 2009). The findings of rapid
labeling of glutamine by 13C-labeled glucose that is predomi-
nantly metabolized in the neuronal compartment are corrobo-
rated by 15N MRS studies of 15NH3 labeling of glutamine in a
hyperammonemia model (Shen et al., 1998). Preferential label-
ing of the predominantly astroglial glutamine can be achieved by
utilizing either the glia-specific anaplerotic pathway or the prefer-
ence for acetate by glial cells. Using [2-13C] glucose or [2,5-13C2]
glucose infusion, rapid transfer of 13C labels from glutamine C3
and C2 to glutamate C3 and C2 was observed (Sibson et al.,
2001). Similarly, when the glia-specific substrate acetate is infused
glutamine is labeled first followed by glutamate reflecting the
transfer of 13C labels from astroglia to neurons (Lebon et al.,
2002; Deelchand et al., 2009). The numerous in vivo 13C- and
15N MRS studies since 1994 by different laboratories have con-
sistently concluded: (1) glutamate–glutamine cycling is a major
metabolic pathway with a flux rate substantially greater than
those suggested by early studies of cell cultures and brain slices;
(2) the glutamate–glutamine cycle is coupled to a large portion
of the total energy demand of brain function (Rothman et al.,
2011).
Extracting quantitative flux rates from any metabolic study
requires modeling, which, historically, has led to controversial
results with few exceptions. The dual roles of glutamate as the
principal neurotransmitter in the CNS and as a key metabolite
linking carbon and nitrogen metabolismmake it possible to probe
glutamate neurotransmitter cycling using MRS by measuring
the labeling kinetics of glutamate and glutamine. At the same
time, comparing to non-amino acid neurotransmitters, the added
complexity makes it more challenging to quantitatively sepa-
rate neurotransmission events from metabolism. Although the
findings from in vivo MRS studies are in agreement that the
glutamate–glutamine cycle is a major metabolic pathway flux
reflecting presynaptic glutamate release, significantly different
cycling rates have been reported by different laboratories for
the same or similar physiological conditions (Gruetter et al.,
2001; Shen and Rothman, 2002; Shestov et al., 2007; Rothman
et al., 2011). Since the MRS measures total glutamate and glu-
tamine the absolute rates of 13C labeling kinetics depend on
the rate of the exchange of TCA cycle intermediates across the
inner mitochondrial membrane (Vx). Evidence for both a fast
exchange (i.e., Vx  VTCA; Mason et al., 1995; de Graaf et al.,
2004; Patel et al., 2004; Yang et al., 2009) and a slow exchange
(i.e., Vx ≈ VTCA; Gruetter et al., 2001; Berkich et al., 2005)
has been presented in the literature. Part of the controversy
surrounding the magnitude of Vcyc can be traced to whether
Vx  VTCA or Vx ≈ VTCA is used in the two-compartment
model.
In addition to the Vx issues, a recent study claimed that, with
the signal-to-noise ratio achievable by in vivo MRS, it is very
difficult, if possible, to quantitatively determine the glutamate–
glutamine cycling rate at a useful precision (Shestov et al., 2007).
Over the past few years our understanding of the neuronal-
astroglial two-compartment metabolic model of the glutamate–
glutamine cycle has been greatly advanced. In particular, the
importance of isotopic dilution of glutamine in determining
the glutamate–glutamine cycling rate using the glutamate-to-
glutamine label transfer has been demonstrated (Shen et al., 2009)
and reproduced (Duarte et al., 2011; Shestov et al., 2012). Recent
publications from different laboratories have shown a clear con-
sensus that glutamate–glutamine cycling rate can be determined
using in vivoMRS with high precision (Boumezbeur et al., 2010a;
Duarte et al., 2011; Rothman et al., 2011; Shestov et al., 2012).
Most recently, by analyzing 13C MRS experiments performed by
several laboratories in both rats and humans which measure both
neuronal energy consumption and glutamate–glutamine cycling,
the Yale group has shown that different studies (both human
and animal studies) are highly consistent in terms of the rela-
tionship between neuronal energy consumption and the rate of
the glutamate–glutamine cycle, which shows that ∼80% of the
resting energy consumption in the awake brain is coupled to
neuronal activity (Hyder and Rothman, 2012). In this article,
we first give an overview of the two-compartment glutamate–
glutamine cycle model. To highlight the main features and
implications of the glutamate–glutamine cycle, a simplified two-
compartment model that captures the major 13C label flows is
analyzed in detail. Recent developments in two-compartment
modeling of the glutamate–glutamine cycle are reviewed. In
particular, the effects of isotopic dilution of glutamine on vari-
ous labeling strategies for determining the glutamate–glutamine
cycle are analyzed in detail. Experimental strategies for measur-
ing the absolute rate of the glutamate–glutamine cycling flux
that are insensitive to isotopic dilution of glutamine are also
suggested.
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THE TWO-COMPARTMENT MODEL OF THE
GLUTAMATE–GLUTAMINE CYCLE
Important metabolic couplings exist among various cells through
the use of common substrates and the exchange of several
metabolic intermediates such as glutamate, glutamine, and γ-
aminobutyric acid (GABA) (Erecin´ska and Silver, 1990; Cerdán
et al., 2006). Because glutamate also acts as the major excitatory
neurotransmitter in the CNS, the neurotransmission of gluta-
mate is intimately related to the metabolism of glutamate and
glutamine. To quantitatively model glutamate metabolism and its
neurotransmission in the CNS, Sibson et al. (1997) proposed a
quantitative two-compartment model describing the glutamate–
glutamine cycle between neurons and astroglia (Figure 1). In
this model, glutamate released by glutamatergic neurons into the
synaptic cleft is taken up by surrounding astroglia and converted
into its inactive form glutamine by the glia-specific glutamine
synthetase. The abundant expression of high capacity glutamate
transporters on glial cell membrane ensures that the extracel-
lular glutamate concentration is kept very low in normal brain
to avoid excitotoxicity. To replenish the neuronal carbon lost to
astroglia, resulting from synaptic glutamate release, glutamine
is released by astroglia and recycled back to neurons where it
is hydrolyzed into glutamate by glutaminase. The model shown
in Figure 1 imposes mass balance constraints for all carbon and
nitrogen fluxes across the blood–brain barrier and between neu-
rons and astroglia at metabolic steady state. At metabolic steady
state, the rate of glutamate release by nerve terminals, the subse-
quent uptake and glutamine synthesis by and in astroglial cells,
as well as glutamine uptake and conversion into glutamate in
neurons are equal (Vcycle). The rate of glutamine synthesis (Vgln)
is the sum of the rate of anaplerotic de novo glutamine synthe-
sis in the astroglia (Vana), the glial-specific process in which CO2
and pyruvate derived from glucose are converted into oxaloac-
etate by pyruvate carboxylase (Berl et al., 1963), and the rate of
the glutamate–glutamine cycle between neurons and astroglia:
VGln = Vcyc + Vana (1)
In addition, the Sibson et al. model connects Vana to the net
uptake of anaplerotic precursors from the blood. At the metabolic
steady state, glutamine efflux (Vefflux) is balanced by glutamine de
novo synthesis via anaplerosis (Vana):
Vana = Vefflux (2)
Following CO2 fixation, oxaloacetate is converted into gluta-
mate either by ammonia fixation (VNH3) or transamination. Glial
glutamate is subsequently converted to glutamine by glutamine
synthetase.
The above model describes the same glutamate–glutamine
cycle proposed decades ago (Hertz, 1979; Erecin´ska and Silver,
1990). The key difference lies in the interpretation of the rapid
glutamine labeling observed using in vivo MRS. To illustrate
the labeling of glutamate and glutamine, a different illustration
of the glutamate–glutamine cycle is shown in Figure 2, where
the coupling between the glutamate–glutamine cycle and energy
metabolism is explicitly shown.
In Figure 2, with infusion of 13C-labeled glucose 13C labels
are mainly incorporated into neuronal glutamate first, accom-
panying the intensive metabolic activities in neurons. Although
FIGURE 1 | Schematic representation of the glutamate–glutamine
cycle between neurons and astroglia and the ammonia
detoxification pathway (adapted from Sibson et al., 1997). Released
neurotransmitter glutamate (Glu) is transported from the synaptic
cleft to surrounding astroglial end processes. Once in the astroglia,
glutamate is converted to glutamine (Gln) by glutamine synthetase.
Glutamine is released by the astroglia, transported into the neurons,
and converted to glutamate by glutaminase, which completes
the cycle. The net rate of glutamine synthesis reflects both
glutamate–glutamine neurotransmitter cycling (Vcyc) and anaplerosis
(Vana). NH3, ammonia; VNH3, ammonia fixation; Vgln, glutamine
synthesis; Glc, glucose; α-KG, α-ketoglutarate.
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FIGURE 2 | Schematic illustration of the glutamate–glutamine cycle
between neurons and astroglia and glucose metabolism (adapted from
Shen et al., 1999). Released neurotransmitter glutamate is transported
from the synaptic cleft by surrounding astroglial end processes. In astroglia,
glutamate is converted into glutamine by glutamine synthetase. Glutamine is
then released by the astroglia, transported into the neurons, and converted
back into glutamate by glutaminase, which completes the cycle. Glc, glucose;
Pyr/Lac, pyruvate/lactate; OAA, oxaloacetate; α-KG, α-ketoglutarate; Glu,
glutamate; Gln, glutamine; CMRglc, cerebral metabolic rate of glucose
utilization; Vana, anaplerotic flux for de novo synthesis of oxaloacetate; aVTCA,
astroglial tricarboxylic acid cycle flux; Vcyc, glutamate–glutamine cycling flux;
nVTCA, neuronal tricarboxylic acid cycle flux.
seldom emphasized in the literature, it is important to point out
that the labeling of glutamate and glutamine is on a very slow
time scale when compared to the rapid vesicular release of glu-
tamate and its uptake by astroglia. Experimentally, the in vivo
turnover time constant of glutamate and glutamine is roughly
one hour at resting state in the human brain. At this time scale,
there is essentially no distinction between neurotransmitter pool
and metabolic pool of glutamate as far as the labeling of the glu-
tamate and glutamine are concerned. It is not surprising that,
using in vivo microdialysis and mass spectrometry to determine
the labeling of extracellular glutamate and glutamine, neuronal
glutamate (through glutamate–glutamine cycling) was found to
be the precursor for 80–90% of astroglial glutamine synthesis
(Kanamori et al., 2003). Therefore, on the time scale of gluta-
mate and glutamine turnover the experimental observation of
rapid labeling of glutamine, which is predominantly located in
astroglial cells, lead to the logical conclusion that neuronal gluta-
mate is the main metabolic precursor of astroglial glutamine via
the glutamate–glutamine cycling flux. In a subsequent analysis of
energy cost associated with the glutamate–glutamine cycle Sibson
et al. (1998) noticed that glutamate uptake into astroglial cells
and its subsequent conversion to glutamine there costs two ATPs.
This energy cost is matched by the number of ATPs produced
by astroglial glycolysis. By extending the Magistretti hypothesis
(Pellerin and Magistretti, 1994) that atroglial glycolysis is cou-
pled to glucose oxidative in neurons Sibson et al. proposed that,
although the glutamate–glutamine cycling uses two ATPs in the
astrocytic portion of the cycle, the full cycle itself is coupled to the
production of a 36 ATPs per glutamate release which are thought
to be mostly used for other activities in the brain.
The identification of neuronal glutamate as the main
metabolic precursor of astroglial glutamine via the glutamate–
glutamine cycling flux leads to a simplified (while conceptually
clearer) model of the glutamate–glutamine cycle (see Figure 3),
which captures the main feature of intercompartmental traffick-
ing of glutamate and glutamine molecules (Shen et al., 2009).
Note that in Figure 3, the astroglial dilution flux, which will be
elaborated later, was explicitly added at the level of glutamine.
This simplified model represents the dominant metabolic rela-
tionship between neuronal glutamate and astroglial glutamine
in the brain. That is, when [1-13C] or [1,6-13C2] glucose infu-
sion is used to introduce exogenous 13C labels into the brain,
most labels flow from pyruvate C3 to neuronal glutamate C4 and
then to astroglial glutamine C4. To better illustrate the concep-
tual aspects of modeling of the glutamate–glutamine cycle this
simplified model will be repeatedly referred to.
In vivo MRS METHODS
Both 13C and 15NMRSmethods have been developed and used to
determine the glutamate–glutamine cycling rate. 13C MRS meth-
ods have been applied to both human subjects and animals while
15N MRS methods are limited to animal models of hyperam-
monemia. Only the 13C MRS methods are summarized here.
Table 1 lists various 13C-related MRS techniques for studying
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FIGURE 3 | The simplified two-compartment model in which all 13C
labels flow from pyruvate/lactate to neuronal glutamate, which is in
exchange with astroglial glutamine (adapted from Shen et al., 2009).
This simplified model represents the dominant metabolic pathways for the
cycling of 13C labels when [1-13C] or [1,6-13C2] glucose infusion is used to
introduce exogenous 13C labels into the brain. As captured by the simplified
model, most 13C labels flow from pyruvate C3 to neuronal glutamate C4
and then to astroglial glutamine C4. The astroglial dilution flux was explicitly
added at the level of glutamine.
Table 1 | Heteronuclear MRS methods for studying the
glutamate–glutamine cycle using infusion of 13C-labeled substrates.
13C{1H} Detect aliphatic carbons such as glutamate C4 and glutamine
C4; use either carbon excitation or proton excitation and
subsequent proton-to-carbon polarization transfer; need high
power coherent proton decoupling (de Graaf et al., 2011)
Detect carboxylic carbons such as glutamate C5 and glu-
tamine C5; use carbon excitation; can use low power stochas-
tic proton decoupling (Li et al., 2009)
1H{13C} Detect aliphatic protons such as glutamate H4 and glutamine
H4; use proton excitation and proton detection; need high
power coherent carbon decoupling (de Graaf et al., 2011)
the CNS, especially the glutamate–glutamine cycle. They fall into
two main categories based on the choice of observed nucleus
(13C or 1H). Generally, 13C detection affords more spectral
information. In the aliphatic (carboxyl/amide) spectral region,
glutamate and glutamine C2–C4 (C1 and C5) carbons can be
measured. Proton detection methods (POCE) have higher sen-
sitivity at the expense of more spectral overlap. 1H{13C} methods
that incorporate proton editing are yet to be fully developed.
LABELING STRATEGIES
Accompanying the advancement of in vivoMRS technology many
methods have been developed for labeling glutamate and glu-
tamine by administering 13C-labeled exogenous substrates (e.g.,
Sibson et al., 1997, 2001; Blüml et al., 2002; Lebon et al., 2002;
Deelchand et al., 2009). The most commonly used substrate
is D-glucose, which is the primary source of energy for brain
metabolism and function under normal physiological conditions.
As shown by Figure 3, with infusion of [1-13C] or [1,6-13C2] glu-
cose 13C labels are mainly incorporated into neuronal glutamate
C4 first. Since neuronal glutamate is the main metabolic precur-
sor of astroglial glutamine via the glutamate–glutamine cycling
flux, 13C label incorporation into glutamine C4 occurs mainly via
the glutamate–glutamine cycling pathway (Vcyc). The simplified
model shown in Figure 3 excludes the contribution to the label-
ing of glutamine C4 via the internal TCA cycle of the astroglial
cells, assumed to be small. Subsequent turns of the TCA cycles
move the 13C labels into C3, C2, C1 of glutamate and glutamine,
and eventually carbon dioxide. 13C labels on the C3 and C2 car-
bons of glutamate and glutamine can be readily detected in the
aliphatic carbon region of the spectra and their labeling kinetics
may be used to improve the determination of the glutamate–
glutamine cycling rate. Since the exact contribution to the labeling
of glutamine C4 by oxidative metabolism in astroglial cells is
difficult to measure by the use of [1-13C] or [1,6-13C2] glucose
alone, alternative labeling strategies for in vivo 13CMRS have been
developed and applied to measuring the glutamate–glutamine
cycling rate.
In addition to the main pathway of 13C label flow depicted
by the simplified model of Figure 3, the astroglial anaplerotic
pathway (Vana) was explicitly shown in Figures 1 and 2. The
primarily astroglial anaplerotic pathway in the CNS offers an
alternative route, albeit less effective than Vcyc, of incorporating
13C labels into glutamate and glutamine. By the action of the
astroglial enzyme pyruvate carboxylase (Patel, 1974) 13C labels
originated from [1-13C] or [1,6-13C2] glucose labels pyruvate C3.
Through CO2 (either 13CO2 or 12CO2) fixation the astroglial
anaplerotic pathway generates the TCA cycle intermediate [3-13C]
or [3,4-13C2] OAA, which through the first turn of the TCA cycle,
labels C2 of α-ketoglutarate, followed by C2 of glutamate and glu-
tamine. Label scrambling at fumarate due to potential backward
flux from OAA to fumarate will label glutamate and glutamine
C3 in the first turn of the TCA cycle as well (Merle et al., 1996;
Brekke et al., 2012). Depending on if the acetylCoA that con-
denses with OAA generated by CO2 fixation is labeled or not by
the infused [1-13C] or [1,6-13C2] glucose, then either [2-13C] glu-
tamine or [2,4-13C2] glutamine is produced during the first turn
of the astroglial TCA cycle. Unfortunately, the weak glutamine
13C NMR signal contributed by astroglial anaplerosis is strongly
masked by the much larger contribution from neuronal oxidative
metabolism and the main route of 13C label incorporation into
glutamine via the glutamate–glutamine cycle (Vcyc).
The strong interference from the heavy 13C traffic coming
from neurons, fortunately, can be more or less eliminated by
choosing [2-13C] or [2,5-13C2] glucose instead of [1-13C] or
[1,6-13C2] glucose (Badar-Goffer et al., 1992). The primary route
of 13C labeling from [2-13C] or [2,5-13C2] glucose leads to
labeling of pyruvate C2 followed by glutamate and glutamine
C5 after the first turn of the TCA cycles. Parenthetically, this
fact also prompted the development of carboxyl/amide carbon
MRS with low power stochastic proton decoupling (Li et al.,
2009). Without the anaplerotic pathway only natural abundance
(1.1%) 13C signals are expected in the aliphatic carbon spectral
region, with the possible exception of minor contributions that
may arise from isotopic impurity of the infused glucose, label
scrambling via hepatic gluconeogenesis, the pentose phosphate
shunt and pyruvate recycling (Cerdán et al., 1990). The major
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contribution to the aliphatic 13C signals therefore comes from
the astroglial anaplerotic pathway. Through CO2 (either 13CO2
or 12CO2) fixation catalyzed by the astroglial enzyme pyruvate
carboxylase the astroglial anaplerotic pathway generates the TCA
cycle intermediate [2-13C] or [2,4-13C2] OAA. As a result, the
13C labeling via the astroglial anaplerotic pathway labels C3
of astroglial glutamate (and glutamine) during the first turn
of the astroglial TCA cycle. Since the heavy 13C traffic gener-
ated inside neurons labels carboxyl/amide carbons the kinetics
of 13C label flow from astroglial glutamine C3 to neuronal glu-
tamate C3 could be measured if sensitivity of the method is
sufficient. An independent measurement of the more elusive
astroglial TCA cycle rate could also be achieved (Sibson et al.,
2001).
The sensitivity of the above approach is ultimately limited by
the much smaller Vana. It is expected that with high magnetic
field strength and indirect detection of glutamine and glutamate
H3 (with the aid of selective 1H and/or 13C editing to separate
glutamate and glutamine H3 signals) further improvements in
the determination of the astroglial TCA cycle rate may be pos-
sible. Nevertheless, at metabolic and isotopic steady state, the
Vcyc/neuronal VTCA (Vcyc/nVTCA) ratio can be reliably measured.
This is because the steady state signal of glutamate C3, in this
case, results from a balance among the fluxes which feed label
from astroglial glutamine C3 via the glutamate–glutamine cycle
and outgoing fluxes to the astroglial glutamine C3 and label
scrambling to other carbon positions by the neuronal TCA cycle.
A similar measurement of 13C label flow from astroglial glu-
tamine to neuronal glutamate can be made by taking advantage
of the glial specific substrate acetate (Muir et al., 1986; Waniewski
and Martin, 1998). Prolonged incubation of neuron culture with
13C-labeled acetate showed no enrichment of 13C labels in gluta-
mate, glutamine, or GABA (Sonnewald et al., 1993). Exogenous
[2-13C] acetate is metabolized via astroglial acetate-CoA ligase
and TCA cycle, and subsequently produces [4-13C] glutamine.
Then, 13C labels enter neuronal compartments via the glutamate–
glutamine cycling flux to produce [4-13C] glutamate. Because of
the high specificity of acetate metabolism [2-13C] acetate has been
used in vivo to quantitatively characterize astroglial metabolism
in the human brain (Blüml et al., 2002; Lebon et al., 2002).
When [1-13C] acetate, instead of [2-13C] acetate, is adminis-
tered, the primary route of intercompartmental 13C label trans-
fer is from astroglial glutamine C5 to neuronal glutamate C5.
Unlike the avid utilization of glucose by brain, the rate of 13C
label transfer from acetate to glutamine and glutamate is signif-
icantly slower, making direct measurement of the absolute rate
of metabolic fluxes by in vivo MRS more challenging, especially
on human subjects. Again, similar to the strategy adopted for
probing 13C label flow from astroglial glutamine to neuronal
glutamate using [2-13C] or [2,5-13C2] glucose, the Vcyc/nVTCA
flux ratio can be measured at metabolic and isotopic steady
state during [2-13C] acetate infusion (Lebon et al., 2002). This
is because the steady state signal of glutamate C4 reflects a bal-
ance among the fluxes that feed label from astroglial glutamine C4
via the glutamate–glutamine cycle and the outgoing fluxes to the
astroglial glutamine C4 and label shift to C3 by the neuronal TCA
cycle. A detailed mathematical treatment is given in the section
“Effects of glutamine isotopic dilution on the determination of
the glutamate–glutamine cycling rate.”
Like acetate, monocarboxylic acids such as β-hydroxybutyrate
(bHB) and lactate readily cross the blood brain barrier via the
monocarboxylate transporters and are utilized as fuels. Both
13C-labeled bHB and lactate have been used to assess 13C label
incorporation into brain glutamate and glutamine (Kunnecke
et al., 1993; Pan et al., 2002; Tyson et al., 2003; Boumezbeur et al.,
2010b; Jiang et al., 2011; Xiang and Shen, 2011a). Tissue culture
studies of neonatal and embryonic mouse cortex (Lopes-Cardozo
et al., 1986) have reported that the majority of the bHB con-
sumed in neurons is oxidized, whereas in astroglial cells it is only
20%. Thus, bHB oxidation should be more indicative of neuronal
metabolism than astroglial metabolism. But unlike the high com-
partmental specificity associated with acetate, oxidation of bHB
by both neuronal and astroglial TCA cycles has to be modeled in
metabolic pathway analysis. The situation is similar for the case
of 13C-labeled lactate infusion. Similar to glucose, oxidation of
lactate by both neuronal and astroglial TCA cycles needs to be
modeled although the majority of plasma lactate is metabolized
in neurons (Boumezbeur et al., 2010b).
DIFFERENTIAL EQUATIONS OF THE GLUTAMATE–GLUTAMINE
CYCLE
The 13C labeling dynamics implied in the two-compartment
model depicted in Figures 2 and 3 can be described explicitly
using coupled linear differential equations, following standard
theory of chemical kinetics. That is, the rate of change in concen-
tration equals the sum of total incoming fluxes minus the sum of
total outgoing fluxes. Here we use the in vivo time courses of the
[4-13C] glutamate and [4-13C] glutamine concentrations mea-
sured during infusion of [1-13C] or [1,6-13C2] glucose as a simple
illustration. The two-compartment metabolic model is shown in
Figure 2. As described by the equations below, 13C label enters the
[4-13C] glutamine pool from both neuronal [4-13C] glutamate,
which is taken up by astroglia, and directly from the astroglial
TCA cycle coupled to the anaplerotic pathway.
ASTROGLIAL COMPARTMENT
Based onmetabolic steady-state considerations, the only net path-
ways of glutamine synthesis (VGln) are the glutamate–glutamine
cycle (Vcyc) and de novo glutamine synthesis by the anaplerotic
pathway (Vana) (Equation 1). The enrichment of the astroglial
[4-13C] glutamate pool can be calculated using the standard
small pool assumption that the pool size is small enough to be
approximated as instantaneously reaching isotopic steady state
with the isotopic fluxes passing through the pool. Experimental
evidence for this assumption of a relatively small glutamate
pool in astrocytes comes from glutamate immunocytochemistry
(Ottersen et al., 1992), studies showing that the enrichment in
glutamine from infused 13N and 15N ammonia is several times
greater than that of glutamate (Cooper et al., 1979), and esti-
mates based on in vivo 13C MRS (Lebon et al., 2002). The reversal
of the normal product-precursor relationship during ammonia
fixation is seen as evidence that the astroglial glutamate pool is
much smaller than the glutamine pool and undergoes rapid iso-
topic turnover. The steady state equation for the concentration
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of astroglial [4-13C]-glutamate ([aGlu4∗]) is given by Shen et al.
(1999):
d[aGlu4∗]/dt = aVTCA[Lac3∗]/[Lac] + Vcyc[nGlu4∗]/[nGlu]
− (Vcyc + Vana)[aGlu4∗]/[aGlu]
− (aVTCA − Vana)[aGlu4∗]/[aGlu] = 0 (3)
where aVTCA is the astroglial tricarboxylic acid cycle flux, Vcyc is
the glutamate–glutamine cycle flux, and Vana is the anaplerotic
flux. [Lac3∗]/[Lac] denotes the fractional enrichment of the
label feeding flux at pyruvate dehydrogenase in astrocytes (The
exchange between lactate and pyruvate catalyzed by lactate
dehydrogenase is much faster than the rate of the pyruvate
dehydrogenase reaction.). [nGlu4∗]/[nGlu] denotes the fractional
enrichment of the neuronal glutamate pool. The labeling of
astroglial [4-13C] glutamine is described by
d[aGln4∗]/dt = VGln[aGlu4∗]/[aGlu] − Vcyc[aGln4∗]/[aGln]
− (Vefflux + Vdil(Gln))[aGln4∗]/[aGln] (4)
where VGln is the total glutamine synthesis rate, Vefflux is the net
glutamine efflux rate, and Vdil(Gln) is the flux term that accounts
for the additional isotopic dilution of glutamine observed experi-
mentally (vide infra).
NEURONAL COMPARTMENT
The labeling of the neuronal [4-13C] glutamine pool can
be described by the same small pool isotopic steady-state
assumption:
d[nGln4∗]/dt = Vcyc([aGln4∗]/[aGln]
− [nGln4∗]/[nGln]) = 0 (5)
The 13C labeling kinetics of the neuronal glutamate pool is given
by
d[nGlu4∗]/dt = nVTCA[Lac3∗]/[Lac] + Vcyc[nGln4∗]/[nGln]
− (Vcyc + nVTCA)[nGlu4∗]/[nGlu] (6)
where nVTCA is the neuronal tricarboxylic acid cycle flux. If the
input plasma glucose concentration and [1-13C] or [1,6-13C2]
glucose fractional enrichment time courses can be described
using simple analytical functions the coupled differential equa-
tions (3–6) can be solved exactly using either inverse Laplace
transform or eigen value decomposition. Since the real arterial
input function is time-varying and coupled to glucose trans-
port kinetics numerical, iterative methods are used in practice
to derive Vcyc by minimizing the least-square difference between
the calculated and measured values for [Glu4∗] and [Gln4∗].
The time courses of glutamate and glutamine C3 (and C2) mea-
sured during infusion of [1-13C] or [1,6-13C2] glucose can be
described mathematically using the same principle. Similarly, the
time courses of 13C-labeled glutamate and glutamine measured
using other labeling strategies can also be modeled to extract
metabolic fluxes of interest.
Instead of attempting to summarize the full sets of differential
equations applicable to individual labeling strategies we exam-
ine the differential equations for the simplified two-compartment
model depicted in Figure 3, which captures the main features of
the full two-compartment model shown in Figure 2. In particular,
the effects of isotopic dilution of glutamine on various labeling
strategies for determining the glutamate–glutamine cycling rate
are illustrated using the simplified two-compartment model.
ORIGINS OF GLUTAMINE ISOTOPIC DILUTION
Although the complete TCA cycle is known to occur exclu-
sively in mitochondria many enzymes involved in the TCA cycle
in brain (e.g., malate dehydrogenase, aconitase, and isocitrate
dehydrogenase) are found in the cytosol of neurons and astro-
cytes as well (Koen and Goodman, 1969; Siesjo, 1978; Rodrigues
and Cerdán, 2006). Only brain pyruvate dehydrogenase, citrate
synthase, fumarase, succinate dehydrogenase and succinate thiok-
inase are exclusively mitochondrial (e.g., Siesjo, 1978; Akiba et al.,
1984; Lai et al., 1989; Rodrigues and Cerdán, 2006). Many TCA
cycle intermediates outside the mitochondria are in exchange
with their mitochondrial counterparts via various transporters
and channels. In terms of metabolic modeling the above pro-
cesses contribute to “isotopic dilution” because a net loss of 13C
labels occurs via exchange with unlabeled cytosolic pools which
are connected to non-TCA cycle pathways. In addition, the net
oxidation of (unlabeled) non-glucose fuels in brain is significant
despite that glucose is the major source of carbon oxidized in
the TCA cycles of brain cells under normal physiological condi-
tions. As described in “Labeling strategies” the contributions of
several non-glucose fuels to brain metabolism have been probed
by administering the fuel source labeled with 13C. Despite the
inflows of unlabeled substrates, the TCA cycle rate can still be cor-
rectly determined by incorporating isotopic dilution pathways in
the metabolic models. The experimentally determined fractional
enrichment of glutamate C4 was smaller than that expected with
[1-13C] or [1,6-13C2] glucose being the sole carbon source for
glutamate. This dilution includes contributions from the influx
of unlabeled substrates from blood and cytosol, including lactate,
pyruvate, ketone bodies, free amino acids, as well as amino acids
produced by protein degradation. On the basis of a quantitative
analysis of various carbon flows into brain reported in the lit-
erature, lactate was considered to be the major contribution to
this dilution under normal physiologic conditions (Mason et al.,
1995). Hence, Vdil(Lac) has been used to represent the lumped
effect of these dilution fluxes.
In addition to the isotopic dilution effect observed at gluta-
mate, astroglial dilution flux accounts for an additional 26% of
label dilution at glutamine C4 (Shen et al., 1999). A detailed
analysis of glutamate and glutamine dilutions has been given by
Dienel and Cruz (2009). There are several potential sources of
this dilution although it is unclear if any single source dominates.
Astroglial glutamine is in exchange with unlabeled glutamine in
blood across the blood–brain barrier (Vefflux, see Figure 1), pri-
marily mediated by N-system transporters (Bröer and Brookes,
2001). Oxidation of short- and medium-chain free fatty acids
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(e.g., acetate and bHB) occur significantly in the astroglia with
acetate regarded as an astroglial specific substrate. 14C-acetate
(Cruz et al., 2005) and 13C-octanoate (Ebert et al., 2003) studies
showed that these endogenous free fatty acids at basal blood levels
contribute significantly to astroglial oxidation (see Table 2). For
example, Cruz et al. (2005) found that, depending on brain region
and level of activity, acetate utilization may provide 28–115%
of total astroglial oxidation. Oxidation of these free fatty acids
undoubtably generates unlabeled acetyl-CoA leading to addi-
tional label dilution at glutamine C4. Branched chain amino
acids readily cross the blood–brain barrier and can act as a
fuel source in the brain (Hutson et al., 2005). [U-14C] leucine
injected systemically was found to label brain glutamine, gluta-
mate, and aspartate in early neurochemical research (Patel and
Balázs, 1970). Therefore, branched chain amino acids metab-
olized to acetyl-CoA or glutamate also contribute to isotopic
dilution of glutamine C4. As a result of the additional isotopic
dilution in astroglial cells, the fractional enrichment of glutamine
C4 is significantly lower than glutamate C4 at all times during
[1-13C] or [1,6-13C2] glucose infusion, including the isotopic
steady state. Similar to the case of Vdil(Lac), we use a single flux
term Vdil(Gln) to represent the lumped glutamine dilution fluxes,
including dilutions at both glutamine and acetyl-CoA levels.
EFFECTS OF GLUTAMINE ISOTOPIC DILUTION ON THE
DETERMINATION OF THE GLUTAMATE–GLUTAMINE
CYCLING RATE
The extraction of Vcyc requires metabolic modeling by least
square minimization. In least square minimization, the cost func-
tion is proportional to χ2 when error per data point has the same
Table 2 | 13C labeling strategies for studying the
glutamate–glutamine cycle*
GLUCOSE
[1-13C] or [1,6-13C2] glucose Primary route of label transfer:
glutamate C4 → glutamine C4
Anaplerotic pathway: glutamine C2 →
glutamate C2
[2-13C] or [2,5-13C2] glucose Primary route of label transfer:
glutamate C5 → glutamine C5
Anaplerotic pathway: glutamine C3 →
glutamate C3
ACETATE**
[2-13C]acetate Primary route of label transfer:
glutamine C4 → glutamate C4
[1-13C]acetate Primary route of label transfer:
glutamine C5 → glutamate C5
bHB AND LACTATE
[2,4-13C2]bHB, [3-13C]
lactate
Primary route of label transfer:
glutamate C4 → glutamine C4
[1,3-13C2]bHB, [ 2-13C]
lactate
Primary route of label transfer:
glutamate C5 → glutamine C5
*For simplicity, only intercompartmental label transfer during the first turn of the
TCA cycles is shown.
**Isotope labels originating from 13C-ethanol enter the brain after being con-
verted into acetate in the liver. The labeling pathway for 13C-labeled ethanol is
the same as that of acetate (Xiang and Shen, 2011b).
noise level (von Mises, 1964). In metabolic modeling fluxes are
determined by minimizing χ2. Generally, the terms in χ2 are not
all statistically independent. For non-linear systems, such as the
two-compartment model of the glutamate–glutamine cycle the
analytical derivation of the probability density function for dif-
ferent χ2 at its minimum is very difficult. Even for the simplified
two-compartment model analytical derivation of the probabil-
ity density function for Vcyc remains a daunting task. Instead,
Monte Carlo simulation can be used to accurately assess the reli-
ability of Vcyc. Using the Monte Carlo method, turnover data sets
drawn from the predefined metabolic model are numerically syn-
thesized. Subsequently, the synthesized data are used to determine
both the probability density function of the χ2-statistic, and the
reproducibility of metabolic fluxes extracted using the fitting pro-
cedure. To ensure that the optimization method of choice works
properly for metabolic modeling statistical analysis of χ2 data can
be performed. When the number of noise realizations is suffi-
ciently large, the χ2-statistic should be normally distributed with
a mean value ofN–n and a standard deviation of sqrt[2(N–n)] for
a small set of metabolic fluxes. Here N is the total number of data
points in the turnover curves and n the number of free metabolic
fluxes to be derived from the fit (von Mises, 1964). Therefore,
the mean and standard deviation of χ2 are indicators of the
goodness-of-fit in Monte Carlo analysis. When metabolic fluxes
are derived based on local instead of global minima, significant
deviations from the theoretical χ2-statistic are expected.
[1-13C] OR [1,6-13C2] GLUCOSE INFUSION
The effects of glutamine isotopic dilution on determination of
the glutamate–glutamine cycling rate depend on specific labeling
strategies. For studies utilizing infusion of [1-13C] or [1,6-13C2]
glucose, which produce the maximum MRS signal-to-noise ratio
with direct or indirect detection of aliphatic carbons, explicit
incorporation of the glutamine isotopic dilution flux into the
two-compartment glutamate–glutamine cycling model is criti-
cal. Without the astroglial glutamine dilution flux, the isotopic
steady state fractional enrichment of the downstream glutamine
C4 would have been the same as that of glutamate C4. The
experimentally measured glutamine C4 turnover curve results
from a balance between incoming 13C labeled flux entering
the glutamine pool (e.g., the glutamate–glutamine cycling flux)
and outgoing 13C labeled flux leaving the glutamine pool (e.g.,
glutamate–glutamine cycling flux and the astroglial dilution flux).
The effects of glutamine isotopic dilution on determination of
the glutamate–glutamine cycling rate are best illustrated using the
simplified two-compartment model depicted in Figure 3, which
represents the dominant metabolic pathway for the trafficking of
13C labels in brain between neurons and astroglia. For this simpli-
fiedmodel, the differential equations (4–6) describing the kinetics
of 13C label incorporation into glutamine C4 are simplified into:
d[aGln4∗]/dt = Vcyc[nGlu4∗]/[nGlu] − Vcyc[aGln4∗]/[aGln]
− Vdil(Gln)[aGln4∗]/[aGln] (7)
Note that the above Equation (7) is very similar to the full
differential equation describing the labeling of astroglial glu-
tamine C4 (Equation 4). To arrive at Equation (7), the term
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Vefflux([aGlu4∗]/[aGlu] – [aGln4∗]/[aGln]) in Equation (4) was
omitted. Since the astroglial glutamate pool size is much smaller
than the astroglial glutamine pool size, approximately, we have
[aGlu4∗]/[aGlu] ≈ [aGln4∗]/[aGln], which reduces Equation (4)
to Equation (7). Here we have again applied the standard small
pool approximation although a more accurate description of
the fractional enrichment of the astroglial glutamate pool is
given by Equation (3). Note that the incoming astroglial dilu-
tion flux involves 12C-labeled Gln C4, which does not enter into
Equation (7).
At isotopic steady state, the following is obtained from
Equation (7):
[aGln4∗]/[aGln] = ([nGlu4∗]/[nGlu])Vcyc/(Vcyc + Vdil(Gln)) (8)
Note that, if Vdil(Gln) is incorrectly set to zero, the fractional
enrichment of the down-stream glutamine C4 approaches that
of the upstream glutamate C4 after the initial glucose infusion
period, progressively losing sensitivity to the label-feeding flux
(Vcyc) over time and causing an overall reduced sensitivity to
Vcyc. At isotopic steady state, the fractional enrichments of glu-
tamine C4 and glutamate C4 become identical if Vdil(Gln) = 0.
That is, at isotopic steady state the glutamine C4 curve is inde-
pendent of Vcyc. In contrast, when the Vdil(Gln) term is included
in the differential equation (7) indicates that the whole glutamine
C4 turnover curve is sensitive to Vcyc. This sensitivity is not lost
at isotopic steady state. Unless Vcyc >> Vdil(Gln), the fractional
enrichment of glutamate C4 will always be larger than the frac-
tional enrichment of glutamine C4 when [1-13C] or [1,6-13C2]
glucose is infused. As shown by Equations (7) and (8), Vdil(Gln)
and Vcyc have different effects on the turnover of glutamine C4,
allowing the two fluxes to be separately determined.
The above analysis was validated by the use of the full
two-compartment model shown in Figure 2, the corresponding
full differential equations (3–6), and Monte Carlo simulation
(Shen et al., 2009). Specifically, glutamate C4 and glutamine C4
turnover curves (see Figure 4A) were generated by solving the
differential equations (3–6) describing the full two-compartment
model with the mean metabolic fluxes obtained from Shen
et al. (1999). The total infusion time is 160min with 32 data
points per curve. Gaussian white noise with standard deviation
σ = 0.1μmol/g was added to assess the accuracy and repro-
ducibility of Vcyc. [1-13C] or [1,6-13C2] glucose infusion was
assumed. At the end point of glucose infusion the fractional
enrichment of glutamine C4 is 26% lower than that of gluta-
mate C4 as observed experimentally (Shen et al., 1999). This data
set was fitted with the two-compartment model with suitable
constraints using the simulated annealing method which is well-
known for its robustness in determining global minimum in a
multidimensional error space. Metabolic fluxes were determined
by minimizing the summed square cost function which is propor-
tional toχ2. The above procedure was repeated 100 times with the
same noise variance but with different noise realizations. A prob-
ability density function for Vcyc is shown in Figure 4B. For the
data set shown in Figure 4A the mean χ2 obtained with 100 noise
realizations is 60.8 with a standard deviation of 11.2. Comparison
with the theoretical mean χ2 of 32 × 2 − 4 = 60 and standard
FIGURE 4 | (A) Synthetic glutamate C4 and glutamine C4 turnover curves
(lines) generated by solving the four coupled differential equations
describing the model in Figure 2 with [1-13C] or [1,6-13C2] glucose infusion,
the mean metabolic fluxes, and adding normally distributed noise (dots).
The astroglial dilution is revealed in (A) by comparing the fractional
enrichments of glutamate and glutamine C4. At the end point of glucose
infusion, the concentration of glutamine and glutamate with 13C labels at
C4 is 0.96 and 2.75μmol/g, respectively. The end point fractional
enrichment of glutamine C4 is 26% lower than that of glutamate C4 as
observed experimentally (Shen et al., 1999). (B) An example of the
probability density function for Vcyc with constraints aVTCA ≤ 0.1,
Vdil(Lac) = 0.05, and Vdil(Gln) = 0.14μmol/g/min. (C) The corresponding
probability density function of the “noise level” after fitting (σmin). The mean
χ2 obtained is 60.8 with a standard deviation of 11.2. σmin averaged over
the 100 Monte Carlo data sets is 0.098μmol/g with a standard deviation of
0.009μmol/g. (This image is reproduced from Shen et al., 2009).
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deviation of 11.0 (the theoretical values are obtained when the
number of noise realizations approaches infinity) indicates that
globalminima were found using the simulated annealingmethod.
The χ2 data were also used to calculate the noise level after min-
imization by simulated annealing (σmin). In the above case, σmin
averaged across the 100 simulations is 0.098μmol/g with a stan-
dard deviation of 0.009μmol/g. The corresponding probability
density function of σmin is shown in Figure 4C. Because poor data
fitting caused by false minima was avoided by the use of simulated
annealing the average σmin is expected to be slightly less than the
added noise level (σ) with a relative standard deviation of slightly
less than 10%. This is exactly what was found. This result also
confirmed that the constraints imposed on the metabolic fluxes
did not alter the quality of the fit.
The importance of the glutamine dilution flux in the accu-
racy and precision of determining Vcyc was also assessed using
numerical Monte Carlo simulations with Vdil(Gln) forced to zero.
When Vdil(Gln) is set to zero the 13C-labeled glutamine concen-
tration predicted by the model shown in Figure 2 is higher than
that shown in Figure 4A. To match the concentration of 13C-
labeled glutamine in Figure 4A and the 13C-labeled glutamine
concentration with Vdil(Gln) = 0, the total glutamine concen-
tration needs to be reduced to 2.8mmol/L in the Monte Carlo
simulations because the actual 13C fractional enrichment of glu-
tamine C4 is lower than that of glutamate C4. For a noise level of
σ = 0.2μmol/g, a relative standard deviation of 438%was calcu-
lated for Vcyc, indicating this flux cannot be reliably determined
under the simulated condition [Vdil(Gln) = 0] using the two-
compartment model shown in Figure 2. At the noise level of σ =
0.1μmol/g the relative standard deviation of the calculated Vcyc is
66%.When aVTCA was constrained not to exceed 0.1μmol/g/min
and simultaneously Vefflux was forced to 0.2∗VGln a large reduc-
tion in the uncertainty of Vcyc was found. In all cases investigated
using numerical Monte Carlo simulations a smaller standard
deviation was found when the Vdil(Gln) term was included in
the modeling.
[2-13C] OR [2,5-13C2] GLUCOSE INFUSION
The effects of glutamine isotopic dilution on determination of the
glutamate–glutamine cycling rate using [2-13C] or [2,5-13C2] glu-
cose infusion are expected to be quite different. Glucose labeled
at [2-13C] or [2,5-13C2] is metabolized through glycolysis to
[2−13C] pyruvate, which enters the TCA cycle through one of two
different pathways. Entry of [2-13C] pyruvate through pyruvate
dehydrogenase leads to labeling of glutamate (and glutamine)
at C5, whereas entry through pyruvate carboxylase (anaplero-
sis) leads to labeling of glutamate (and glutamine) at C3 in
the first turn of the TCA cycle followed by C2 and C1 in sub-
sequent turns. Similar to [1-13C] or [1,6-13C2] glucose infu-
sion, potential label scrambling at fumarate during [2-13C] or
[2,5-13C2] glucose infusion labels glutamate and glutamine C2
in the first turn of the TCA cycle (see the “Labeling strate-
gies” section). Half of the 13C labels on glutamate C3 move
to glutamate C2 due to symmetric label scrambling of the
TCA cycle. 13C-labeled glutamate C3 is also in exchange with
13C-labeled glutamine C3 via the glutamate–glutamine cycle.
Using the simplified model shown in Figure 3 the following
differential equation describes the kinetics of 13C-labeled gluta-
mate C3:
d[nGlu3∗]/dt = −0.5nVTCA[nGlu3∗]/[nGlu]
+ Vcyc([aGln3∗]/[aGln] − [nGlu3∗]/[nGlu])
(9)
At metabolic and isotopic steady state, Equation (9) becomes:
Vcyc/
nVTCA = 0.5∗([nGlu3∗]/[nGlu])/([aGln3∗]/[aGln]
− [nGlu3∗]/[nGlu]) (10)
by setting d[nGlu3∗]/dt to zero. Equation (10) is identical to
Equation (4) in Sibson et al. (2001) if a small correction term
([nGlu4∗]/[nGlu]) is ignored. Equation (4) in Sibson et al. (2001)
was derived using the full two-compartment model (Figure 2).
Note that, because Equation (9) describes the kinetics of a pre-
dominantly neuronal signal ([nGlu3∗]), the astroglial Vdil(Gln)
term does not appear in Equations (9) or (10).
To describe the labeling kinetics of glutamine C3 the main
label-feeding flux via the astroglial anaplerotic pathway needs to
be incorporated. The following equation is then obtained:
d[aGln3∗]/dt = Vana[Lac2∗]/[Lac] + Vcyc([nGlu3∗]/[nGlu]
− [aGln3∗]/[aGln]) − Vdil(Gln)[aGln3∗]/[aGln]
(11)
Equation (11) is analogous to Equation (7) for [1-13C] or
[1,6-13C2] glucose infusion. Atmetabolic and isotopic steady state
Equation (11) is reduced to:
Vdil(Gln)/Vcyc = (Vana/Vcyc) × ([Lac2∗]/[Lac])/([aGln3∗]/[aGln])
+ ([nGlu3∗]/[nGlu])/([aGln3∗]/[aGln]) − 1
(12)
The most interesting conclusion of the above analysis of the
effects of astroglial isotopic dilution of glutamine on determining
Vcyc using [2-13C] or [2,5-13C2] glucose infusion is that Vcyc (or
Vcyc/nVTCA if only steady state fractional enrichments of gluta-
mate and glutamine C3 are measured) is insensitive to astroglial
isotopic dilution of glutamine. As described in “Labeling strate-
gies,” the sensitivity of the [2-13C] or [2,5-13C2] glucose infusion
with detection of aliphatic carbons is limited because of the small
Vana flux. Dynamic studies necessary for determining the abso-
lute Vcyc flux may be attempted by boosting sensitivity with high
magnetic fields and indirect proton detection (with 13C or proton
editing to separate spectral overlap between glutamate H3 and
glutamine H3). An alternative experimental strategy also exists.
Recent MRS data of human brain acquired during [2-13C] glucose
infusion have shown that the sensitivity of carboxyl/amide carbon
detection is sufficient for the reliable measurement of glutamate
turnover at 3 Tesla (Li et al., 2009). This would allow determi-
nation of the absolute, predominantly neuronal TCA cycle rate.
Since the recycle delay of the carboxyl/amide carbon MRS exper-
iment is relatively long, interleaved detection of the aliphatic
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glutamate C3 and glutamine C3 signals can be performed in
principle. Then, by adding all the time course data of glutamate
C3 and glutamine C3, the Vcyc/nVTCA ratio can be simultane-
ously measured [by utilizing the integrated form of Equation
(9)]. By combining data from carboxyl/amide and aliphatic spec-
tral regions, Vcyc can be determined independent of Vdil(Gln), in
contrast to the case of [1-13C] or [1,6-13C2] glucose infusion.
[2-13C] ACETATE INFUSION
The insensitivity to astroglial glutamine dilution flux Vdil(Gln) in
the determination of Vcyc by the use of [2-13C] or [2,5-13C2]
glucose infusion is a direct result of extracting Vcyc from signals
(d[nGlu3∗]/dt) of the neuronal compartment (see Equation 9).
In [2-13C] or [2,5-13C2] glucose infusion experiments the flux
causing the increased labeling of glutamate C3 signal comes from
glutamine C3 predominantly located in the astroglia. A similar
scenario can be generated by the use of [2-13C] acetate infu-
sion. During [2-13C] acetate infusion, 13C label from [4-13C]
glutamine enters neuronal compartments via the glutamate–
glutamine cycle to produce [4-13C] glutamate. Here the glutamate
C4 plays the same role as that of glutamate C3 during [2-13C]
or [2,5-13C2] glucose infusion. The corresponding differential
equation describing the labeling kinetics of glutamate C4 is:
d[nGlu4∗]/dt = −nVTCA[nGlu4∗]/[nGlu] + Vcyc([aGln4∗]/[aGln]
− [nGlu4∗]/[nGlu]) (13)
for the simplified two-compartment model shown in Figure 3.
Essentially the same equation is obtained when the full two-
compartment model (Figure 2) was used (Lebon et al., 2002).
Similar to Equation (9), Vcyc, in principle, can be determined
from the 13C MRS turnover data. The sensitivity of the acetate
infusion experiment, however, is only a fraction of that of the cor-
responding [1-13C] or [1,6-13C2] glucose infusion experiment. As
an alternative to dynamic studies, the Vcyc/nVTCA flux ratio can be
determined from spectra acquired at the metabolic and isotopic
steady state where d[nGlu4∗]/dt = 0:
Vcyc/
nVTCA = ([nGlu4∗]/[nGlu])/([aGln4∗]/[aGln]
− [nGlu4∗]/[nGlu]) (14)
Note that, as expected, the astroglial glutamine dilution flux
Vdil(Gln) does not appear in either Equations (13) or (14).
Therefore, Vcyc determined in this manner is also insensitive to
Vdil(Gln).
As well-known in statistics, over-parameterization or over-
fitting of a model leads to increased uncertainty. A familiar
example is spectral fitting in quantification of crowded proton
MRS spectra. When the spectral model is over-parameterized,
erroneous concentration and increased uncertainty are easily
obtained. In the case of [2-13C] or [2,5-13C2] glucose and [2-13C]
acetate infusion experiments described here, the addition of flux
terms [e.g., Vdil(Gln)] to which the data are insensitive (Shestov
et al., 2012) can lead to increased uncertainly in Vcyc.
To extract the absolute flux of the glutamate–glutamine cycle
an independent or simultaneous measurement of VTCA needs to
be performed. In a recent study, difference in brainmitochondrial
metabolism of young and old healthy human subjects was stud-
ied by infusing [1-13C] glucose in one experiment and [2-13C]
acetate to the same subject in a separate experiment (Boumezbeur
et al., 2010a). For [2-13C] acetate infusion experiments, it is pos-
sible to infuse [2-13C] acetate and [2-13C] (or [2,5-13C2]) glucose
simultaneously and measure VTCA in the carboxyl/amide spec-
tral region and measure the Vcyc/nVTCA flux ratio in the aliphatic
spectral region as outlined for the case of [2-13C] or [2,5-13C2]
glucose infusion.
In vivo double-labeling experiments have been performed
recently on both animals (Deelchand et al., 2009; Xiang and Shen,
2011a) and human subjects (Li et al., 2012). Since carboxyl/amide
carbons are located at the end of the carbon skeleton of amino
acids they can form either a singlet if its neighbor carbon is 12C,
or a doublet if its neighbor carbon is 13C, leading to natural sim-
plification of their isotopomer patterns (Xiang and Shen, 2011a).
When 13C-labeled glucose is administered the glutamate and
glutamine C4-C5 moieties are labeled by glucose C1-C2 and/or
C5-C6, regardless of the number of the turns of the TCA cycle.
Consequently, when the input is [1,2-13C2] acetyl-CoA, gluta-
mate C5 and glutamine C5 can only form doublet signals. Vice
versa, when the input is [2-13C] acetyl-CoA glutamate C5 and
glutamine C5 can only form singlet signals. This unique feature of
the carboxyl/amide carbons makes it possible to simultaneously
and unambiguously detect the labeling of glutamate and glu-
tamine by two substrates with the second substrate (e.g., acetate)
producing singlets only. Because of the large one-bond 13C-13C
homonuclear J coupling between a carboxyl/amide carbon and
an aliphatic carbon (∼50Hz), the singlet and doublet signals of
the same carboxyl/amide carbon can be well distinguished. It is
readily conceivable that one may use the glutamate C5 doublet
generated from uniformly labeled glucose to measure the absolute
flux of VTCA and the glutamate C5 and glutamine C5 singlets gen-
erated from [1-13C] acetate to measure the Vcyc/nVTCA flux ratio.
Vcyc measured in this manner is expected to be insensitive to the
astroglial glutamine dilution flux based on the above analysis.
CONCLUSION
In vivo 13C MRS has evolved into a major non-invasive tool
for assessing glutamatergic function in both human subjects
and animal models. Recent development of 13C MRS tech-
niques has been spurred by renewed interest in the glutamate–
glutamine cycle proposed decades ago. Like all metabolic mod-
els the two-compartment glutamate–glutamine cycling model
has generated controversy. While the dual roles of glutamate as
primary excitatory neurotransmitter in the CNS and as a key
metabolite linking carbon and nitrogen metabolism make it pos-
sible to probe glutamate neurotransmitter cycling using MRS
this dual role also requires one to separate neurotransmission
events from metabolism. In spite of the on-going controver-
sies, the in vivo MRS community has made major contribu-
tions to our understanding of brain energy consumption and
the relationship between neuroenergetics and neurotransmission.
Over the past few years our understanding of the neuronal-
astroglial two-compartment metabolic model of the glutamate–
glutamine cycle has been further advanced. In particular, the
Frontiers in Neuroenergetics www.frontiersin.org January 2013 | Volume 5 | Article 1 | 11
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importance of isotopic dilution of glutamine in determining the
glutamate–glutamine cycling rate using [1-13C] or [1,6-13C2]
glucose has been demonstrated and reproduced. It is hoped
that the analysis of the astroglial dilution effects and Vdil(Gln)-
insensitive experimental methods for absolute quantification of
the glutamate–glutamine cycling rate discussed here will fur-
ther advance the field. With the increasing availability of high-
field MR magnets (7 Tesla or higher) and further developments
of MRS techniques characterization of glutamatergic function
by in vivo 13C MRS has the potential to significantly impact
both basic and clinical research in neurological and psychiatric
disorders.
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